Skip to main
ENLV

ENLV Stock Forecast & Price Target

ENLV Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enlivex Therapeutics has established a robust financial strategy by implementing an at-the-market (ATM) offering, enabling the company to leverage elevated trading volumes to enhance liquidity, which is essential for the ongoing development of Allocetra. Promising topline results from Phase IIa trials indicate statistically significant improvements in pain reduction and functionality, particularly in the demographic of patients aged 60 and older suffering from idiopathic age-related osteoarthritis, a substantial segment of the market. Furthermore, the filing of a patent application for Allocetra in osteoarthritis solidifies the company's intellectual property position, reflecting its potential to penetrate a significant unmet need in the musculoskeletal treatment landscape.

Bears say

Enlivex Therapeutics is currently taking time to reassess its strategic direction, prompting a cautious shift in outlook amid uncertainties regarding its capital access and investor engagement tactics. The disconnect between the company's clinical advancements and market recognition raises concerns about its ability to attract necessary investment to support its allogeneic drug pipeline. Additionally, while potential milestones in their KOA program might reduce risks if aligned with previous Phase IIa data, the need for a strategic pivot complicates their financial outlook and may hinder overall growth.

ENLV has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enlivex Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enlivex Therapeutics Ltd (ENLV) Forecast

Analysts have given ENLV a Strong Buy based on their latest research and market trends.

According to 2 analysts, ENLV has a Strong Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enlivex Therapeutics Ltd (ENLV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.